BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 11716230)

  • 1. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
    Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
    Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma.
    Zhang X; Wakabayashi H; Hiromasa T; Kayano D; Kinuya S
    Semin Nucl Med; 2023 Jul; 53(4):503-516. PubMed ID: 36641337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma.
    Killock D
    Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38459158
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to targeted radionuclide therapy with [
    Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
    Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectal Paraganglioma.
    Araki T; Takeshita S; Kawasaki H; Kusumoto K; Ohata K; Shigematsu K; Shigeno M
    Intern Med; 2019 Jan; 58(2):195-199. PubMed ID: 30146582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.
    Canu L; Pradella S; Rapizzi E; Fucci R; Valeri A; Briganti V; Giachè V; Parenti G; Ercolino T; Mannelli M
    Arch Endocrinol Metab; 2017; 61(1):90-97. PubMed ID: 27737332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant pheochromocytoma.
    Adjallé R; Plouin PF; Pacak K; Lehnert H
    Horm Metab Res; 2009 Sep; 41(9):687-96. PubMed ID: 19672813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic therapy of malignant adrenal tumors].
    Horstmann M; Merseburger AS; Stenzl A; Kuczyk M
    Urologe A; 2006 May; 45(5):605-8. PubMed ID: 16622644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple endocrine neoplasia type 2.
    Peczkowska M; Januszewicz A
    Fam Cancer; 2005; 4(1):25-36. PubMed ID: 15883707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
    Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
    QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
    Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
    J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands.
    Hartley A; Spooner D; Brunt AM
    Clin Oncol (R Coll Radiol); 2001; 13(5):361-6. PubMed ID: 11716230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.
    van Hulsteijn LT; Niemeijer ND; Dekkers OM; Corssmit EP
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):487-501. PubMed ID: 24118038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy.
    Sisson JC; Shapiro B; Shulkin BL; Urba S; Zempel S; Spaulding S
    Am J Clin Oncol; 1999 Aug; 22(4):364-70. PubMed ID: 10440191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.